These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

397 related items for PubMed ID: 37907837

  • 1. Predictive value of Dmax and %ΔSUVmax of 18F-FDG PET/CT for the prognosis of patients with diffuse large B-cell lymphoma.
    Dang J, Peng X, Wu P, Yao Y, Tan X, Ye Z, Jiang X, Jiang X, Liu Y, Chen S, Cheng Z.
    BMC Med Imaging; 2023 Oct 31; 23(1):173. PubMed ID: 37907837
    [Abstract] [Full Text] [Related]

  • 2. A better prediction of progression-free survival in diffuse large B-cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUVmax.
    Zhang YY, Song L, Zhao MX, Hu K.
    Cancer Med; 2019 Sep 31; 8(11):5137-5147. PubMed ID: 31343111
    [Abstract] [Full Text] [Related]

  • 3. [18F-FDG PET/CT Metabolic Parameters and Circulating Tumour DNA Mutation Abundance in Diffuse Large B-Cell Lymphoma: Correlation and Survival Analysis].
    Xu HQ, Song LJ, Ding CY.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec 31; 31(6):1690-1700. PubMed ID: 38071047
    [Abstract] [Full Text] [Related]

  • 4. Prognostic Value of 18F-FDG PET/CT in Diffuse Large B-Cell Lymphoma Treated with a Risk-Adapted Immunochemotherapy Regimen.
    Michaud L, Bantilan K, Mauguen A, Moskowitz CH, Zelenetz AD, Schöder H.
    J Nucl Med; 2023 Apr 31; 64(4):536-541. PubMed ID: 36549918
    [Abstract] [Full Text] [Related]

  • 5. Prognostic analysis of interim 18F-FDG PET/CT in patients with diffuse large B cell lymphoma after one cycle versus two cycles of chemotherapy.
    Yuan L, Kreissl MC, Su L, Wu Z, Hacker M, Liu J, Zhang X, Bo Y, Zhang H, Li X, Li S.
    Eur J Nucl Med Mol Imaging; 2019 Feb 31; 46(2):478-488. PubMed ID: 30382301
    [Abstract] [Full Text] [Related]

  • 6. Predictive value of baseline 18F-FDG PET/CT and interim treatment response for the prognosis of patients with diffuse large B-cell lymphoma receiving R-CHOP chemotherapy.
    Zhu L, Meng Y, Guo L, Zhao H, Shi Y, Li S, Wang A, Zhang X, Shi J, Zhu J, Xu K.
    Oncol Lett; 2021 Feb 31; 21(2):132. PubMed ID: 33552253
    [Abstract] [Full Text] [Related]

  • 7. [Values of Different Evaluation Criteria of Interim 18F-FDG PET/CT Scan for Prediction of Prognosis in Patients with DLBCL].
    Zhu LT, Cen XN, Ou JP, Qiu ZX, Wang LH, Liu W, Wang WS, Dong YJ, Liang ZY, Wang MJ, Xu WL, Sun YH, Wang Q, Yin Y, Ren HY.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr 31; 25(2):431-437. PubMed ID: 28446288
    [Abstract] [Full Text] [Related]

  • 8. Interim PET/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B-cell lymphoma.
    Li X, Sun X, Li J, Liu Z, Mi M, Zhu F, Wu G, Lan X, Zhang L.
    Cancer Med; 2019 Sep 31; 8(11):5012-5022. PubMed ID: 31293092
    [Abstract] [Full Text] [Related]

  • 9. Prognostic value of metabolic tumour volume on baseline 18F-FDG PET/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI.
    Shagera QA, Cheon GJ, Koh Y, Yoo MY, Kang KW, Lee DS, Kim EE, Yoon SS, Chung JK.
    Eur J Nucl Med Mol Imaging; 2019 Jul 31; 46(7):1417-1427. PubMed ID: 30941463
    [Abstract] [Full Text] [Related]

  • 10. [Value of 18F-FDG PET/CT Scan Quantization Parameters for Prognostic Evaluation of Patients with Diffuse Large B-cells Lymphoma].
    Zhang YY, Chen WY, Cui YP, Gao XR, Hu JX, Li ZZ, Hu K.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct 31; 26(5):1342-1249. PubMed ID: 30295248
    [Abstract] [Full Text] [Related]

  • 11. Metabolic tumour area: a novel prognostic indicator based on 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma in the R-CHOP era.
    Cui S, Xin W, Wang F, Shao X, Shao X, Niu R, Zhang F, Shi Y, Liu B, Gu W, Wang Y.
    BMC Cancer; 2024 Jul 25; 24(1):895. PubMed ID: 39054508
    [Abstract] [Full Text] [Related]

  • 12. [18F]FDG PET/CT for prognosis and toxicity prediction of diffuse large B-cell lymphoma patients with chimeric antigen receptor T-cell therapy.
    Gui J, Li M, Xu J, Zhang X, Mei H, Lan X.
    Eur J Nucl Med Mol Imaging; 2024 Jul 25; 51(8):2308-2319. PubMed ID: 38467921
    [Abstract] [Full Text] [Related]

  • 13. Prognostic parameters on baseline and interim [ 18 F]FDG-PET/computed tomography in diffuse large B-cell lymphoma patients.
    Czibor S, Carr R, Redondo F, Auewarakul CU, Cerci JJ, Paez D, Fanti S, Györke T.
    Nucl Med Commun; 2023 Apr 01; 44(4):291-301. PubMed ID: 36705233
    [Abstract] [Full Text] [Related]

  • 14. 18F-FDG PET Improves Baseline Clinical Predictors of Response in Diffuse Large B-Cell Lymphoma: The HOVON-84 Study.
    Burggraaff CN, Eertink JJ, Lugtenburg PJ, Hoekstra OS, Arens AIJ, de Keizer B, Heymans MW, van der Holt B, Wiegers SE, Pieplenbosch S, Boellaard R, de Vet HCW, Zijlstra JM, HOVON Imaging Working Group and the HOVON Lymphoma Working Group.
    J Nucl Med; 2022 Jul 01; 63(7):1001-1007. PubMed ID: 34675112
    [Abstract] [Full Text] [Related]

  • 15. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
    Ding CY, Guo Z, Sun J, Yang WP, Li TR.
    Zhonghua Zhong Liu Za Zhi; 2018 Jul 23; 40(7):528-533. PubMed ID: 30060362
    [Abstract] [Full Text] [Related]

  • 16. [The prognosis value of early and interim ¹⁸F-FDG-PET/CT scans in patients with diffuse large B-cell lymphoma].
    Zhang Y, Fan Y, Yang Z, Ying Z, Song Y, Zhu J, Wang X.
    Zhonghua Xue Ye Xue Za Zhi; 2015 Oct 23; 36(10):824-9. PubMed ID: 26477759
    [Abstract] [Full Text] [Related]

  • 17. Dual time point 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer.
    Yamagishi Y, Koiwai T, Yamasaki T, Einama T, Fukumura M, Hiratsuka M, Kono T, Hayashi K, Ishida J, Ueno H, Tsuda H.
    BMC Cancer; 2019 Nov 27; 19(1):1146. PubMed ID: 31775675
    [Abstract] [Full Text] [Related]

  • 18. Prognostic value of the peripheral blood lymphocyte/monocyte ratio combined with 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma.
    Wu W, Zhao L, Wang Y, Chen P, Yuan X, Miao L, Zhu Y, Mao J, Cai Z, Ji Y, Wang L, Jia T.
    Curr Probl Cancer; 2024 Feb 27; 48():101066. PubMed ID: 38364336
    [Abstract] [Full Text] [Related]

  • 19. Validation of the ΔSUVmax for Interim PET Interpretation in Diffuse Large B-Cell Lymphoma on the Basis of the GAINED Clinical Trial.
    Itti E, Blanc-Durand P, Berriolo-Riedinger A, Kanoun S, Kraeber-Bodéré F, Meignan M, Gat E, Gouill SL, Casasnovas RO, Bodet-Milin C.
    J Nucl Med; 2023 Nov 27; 64(11):1706-1711. PubMed ID: 37734837
    [Abstract] [Full Text] [Related]

  • 20. Predictive value of clinical characteristics and baseline 18F-FDG PET/CT quantization parameters in primary adrenal diffuse large B-cell lymphoma: a preliminary study.
    Huang W, Chao F, Li L, Gao Y, Qiu Y, Wang W, Gao J, Han X, Kang L.
    Quant Imaging Med Surg; 2023 Dec 01; 13(12):8571-8586. PubMed ID: 38106313
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.